Will West Email & Phone Number

A clinical stage, cancer therapy biotech company with a deep foundation in epigenetics. Having initially explored cell fate transformation and new drug targets for disease, the company pivoted to oncology drug discovery and development.CellCentric's drug is inobrodib (CCS1477), an oral first-in-class inhibitor of p300/CBP, to treat specific cancers, notably relapsed refractory multiple myeloma.

Morningside is an international private equity and venture capital investor, including significant interests in biotechnology and healthcare.

Cambridge, England, Gb

Digital pathology company, focused on oesophageal cancer. Contracts across the NHS delivering diagnostic services; soon to be launching in the US.

Manchester, England, Gb

F2G is developing a novel (non-azole) clinical anti-fungal agent. Olorofim is in late stage clinical trials, approaching initial commercialisation.

Self-amplifying RNA technology for novel vaccines and other products, building on the work of Robin Shattock and partnership with the Vaccine Task Force for Covid. Collaborative R&D with AZ.

Norwich, Norfolk, Gb

The John Innes Centre is a world-leading research institute focused on plant science, genetics and microbiology. Mission to deliver: Healthy Plants, Healthy People, Healthy Planet. Oversaw next generation infrastructure proposal (>£300m funding), and instigated governance/organisational changes.

London, Gb

The BIA is the trade association for innovative enterprises involved in UK bioscience. Members range from emerging and more established biotech companies through to pharmaceutical corporates, as well as service providers to the bioscience sector.

CTS was developing systemic non-viral gene delivery systems and products for cancer imaging and therapy. The company spun out of Johns Hopkins University, Schools of Medicine and Engineering.

Cambridge, Gb

A cardiovascular research company based at Papworth Hospital, Cambridge. The company's Liquid Biopsy System (LBS) enables simultaneous biological sampling from within coronary arteries, healthy or diseased. Technology of direct use in investigating the function of cardiac-related drugs, as well as understanding the aetiology of heart disease.

Swindon, Wiltshire, Gb

Council Member of the Biotechnology and Biological Sciences Research Council, appointed by David Willetts, Minister of State for Universities and Science. Investing around £0.5bn each year into biological research at universities and institutes across the UK.• Chair: working party for the new Institute for Food & Health• Council link to John Innes Centre, Norwich• Panels: BioScience for Industry; Innovator of the Year; Activating Impact awards (chair)

• Business and product development of cell based and cell derived products. • Established collaborations with 4 of the top 6 multinational orthopaedic companies.

Cincinnati, Ohio, Us

• Managed group across three countries; UK, US and China.• Led clinical trials, phase I to III, across a range of therapeutic areas; Respiratory, GI, Skin. • Wide experience of healthcare claims generation/support and global professional marketing. • Helped established clinical R&D capacity in China. Also managed research and clinical trials in the USA, Eastern Europe and South America.• Designed and ran a training course on healthcare portfolio management.

• MRC AIDS Vaccine Development Programme (WHO affiliated).• Work included research into the role of tissue type proteins and anti-HLA antibodies in protection against HIV immunity. Member of the Vaccine Trials Committee.

Mba (Executive)

Phd, Virology/Immunology: F Protein Of Respiratory Syncytial Virus (Rsv)

Msc (Part Time), Clinical Research